Evidence for use of glatiramer acetate in multiple sclerosis

This publication has 6 references indexed in Scilit:

• Lack of evidence for use of glatiramer acetate in multiple sclerosis
  The Lancet Neurology, 2004
• Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials
  Multiple Sclerosis Journal, 2003
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
  Annals of Neurology, 2001
• Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
  Annals of Neurology, 2000
• Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
  Neurology, 1998
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
  Neurology, 1995